Ranibizumab
Treatment for Macular Degeneration
Typical Dosage: 0.5 mg intravitreal injection every 4 weeks, then individualized
Effectiveness
88%
Safety Score
45%
Clinical Trials
381
Participants
60K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
0.5 mg intravitreal injection every 4 weeks, then individualized
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$16,000
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$17,050
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$75,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$18,532.61
Comparison vs Bevacizumab
Cost Difference
+$15,200/year
More expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Ranibizumab Outcomes
for Macular Degeneration
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+92%
Common Side Effects
Conjunctival hemorrhage
+15%
Eye pain
+8%
Vitreous floaters
+7%
Increased intraocular pressure
+3%
Endophthalmitis
+0.05%
Retinal detachment
+0.05%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
15 completed trials for Ranibizumab in Macular Degeneration
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
NCT00056836COMPLETEDPHASE3
720 participants
INTERVENTIONAL
Started: Mar 1, 2003
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
NCT00095433COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Started: Sep 1, 2002
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
NCT00061594COMPLETEDPHASE3
426 participants
INTERVENTIONAL
Tucson, United States +81 more
Started: May 1, 2003
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
NCT00090623COMPLETEDPHASE3
180 participants
INTERVENTIONAL
Denver, United States
Started: Aug 1, 2004
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707COMPLETEDPHASE1, PHASE2
20 participants
INTERVENTIONAL
Chevy Chase, United States +1 more
Started: Aug 1, 2005
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
NCT00056823COMPLETEDPHASE1, PHASE2
168 participants
INTERVENTIONAL
Started: Mar 1, 2003
Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
NCT01831947COMPLETEDPHASE4
40 participants
INTERVENTIONAL
Göttingen, Germany
Started: Apr 1, 2010
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
NCT02510794COMPLETEDPHASE2
225 participants
INTERVENTIONAL
Mesa, United States +49 more
Started: Sep 28, 2015
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
NCT03805100COMPLETEDPHASE3
582 participants
INTERVENTIONAL
Gilbert, United States +101 more
Started: Apr 19, 2019
Lucentis in Advanced Macular Degeneration
NCT00896779COMPLETEDPHASE2
20 participants
INTERVENTIONAL
San Francisco, United States +1 more
Started: Oct 1, 2009
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
NCT02060604COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Brescia, Italy
Started: Dec 1, 2012
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
NCT02944227COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Seoul, South Korea
Started: Mar 3, 2016
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
NCT00469352COMPLETEDPHASE3
150 participants
INTERVENTIONAL
Portland, United States
Started: May 1, 2007
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
NCT01933152COMPLETED
137 participants
OBSERVATIONAL
Many Locations, Portugal
Started: Aug 1, 2012
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
NCT02420132COMPLETED
47 participants
OBSERVATIONAL
Salt Lake City, United States
Started: Apr 20, 2015
Showing 20 of 382 total trials